Naphazoline: Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Naphazoline
Therapeutic Class: Nasal decongestant
Subclass: Alpha-adrenergic agonist (sympathomimetic)
Specialty: Ophthalmology
Schedule (India): OTC (topical ophthalmic and nasal formulations)
Route(s): Ophthalmic (eye drops), Intranasal (nasal drops)
Formulations Available in India:
- Ophthalmic solution (eye drops): 0.01%, 0.012%, 0.05%
- Nasal drops: 0.05%, 0.1%
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Allergic or Irritant Conjunctivitis / Ocular Hyperaemia (Red Eye)
Formulation: Ophthalmic solution (0.01%, 0.012%, or 0.05%)
Adults:
- Starting dose: 1–2 drops in affected eye(s)
- Titration: Not applicable
- Usual maintenance dose: 1–2 drops every 4–6 hours as needed
- Maximum dose: 4 applications per day; do not exceed 3–5 consecutive days
Clinical Notes:
- Short-term use only to avoid rebound hyperaemia or tachyphylaxis
- Avoid in patients with narrow-angle glaucoma
- Remove contact lenses before instillation; wait 15 minutes before reinsertion
- Discontinue if redness worsens or persists beyond 72 hours
2. Acute Nasal Congestion (Rhinitis / Sinusitis)
Formulation: Nasal drops (0.05% or 0.1%)
Adults:
- Starting dose: 1–2 drops per nostril
- Titration: Not applicable
- Usual maintenance dose: 1–2 drops per nostril every 6–8 hours
- Maximum dose: 3 applications per day; do not exceed 5 consecutive days
Clinical Notes:
- Prolonged use (>5 days) leads to rhinitis medicamentosa (rebound congestion)
- Use 0.05% in patients with cardiovascular disease or hypertension
- Proper technique: tilt head back, instill drops, remain supine for 1–2 minutes
Secondary Indications — Adults (Off-label, if any)
None documented in Indian sources.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
1. Allergic Conjunctivitis / Ocular Hyperaemia
| Age Group | Formulation | Dose | Frequency | Maximum Duration |
| ≥6 years | 0.01% ophthalmic drops | 1 drop in affected eye(s) | 2–3 times daily | 3 days |
| <6 years | Not recommended | — | — | — |
Safety Monitoring:
- Monitor for mydriasis (pupillary dilation)
- Watch for systemic absorption signs: drowsiness, bradycardia, pallor
- Use lowest effective concentration
2. Acute Nasal Congestion (Rhinitis)
| Age Group | Formulation | Dose per Nostril | Frequency | Maximum Duration |
| 6–12 years | 0.05% nasal drops | 1 drop | Up to 3 times daily | 3 days |
| <6 years | Not recommended | — | — | — |
Safety Monitoring:
- Monitor for CNS depression (drowsiness, lethargy)
- Watch for bradycardia, respiratory depression, hypotension
- Avoid concurrent CNS depressants
Secondary Indications — Paediatrics (Off-label, if any)
None documented in Indian sources.
Clear Statement: Not recommended in children <6 years due to high risk of systemic toxicity (CNS depression, bradycardia, respiratory depression). Use only under ENT or paediatric specialist supervision if absolutely necessary.
RENAL ADJUSTMENT
No adjustment required (minimal systemic absorption with topical use).
HEPATIC ADJUSTMENT
| Impairment Level | Recommendation |
| Mild | No specific adjustment; limit to short-term use |
| Moderate | Use with caution; monitor for systemic effects |
| Severe | Avoid use; risk of CNS depression with potential accumulation |
CONTRAINDICATIONS
- Narrow-angle or closed-angle glaucoma (ophthalmic use)
- Known hypersensitivity to naphazoline or formulation excipients
- Severe dry eye syndrome (ophthalmic use worsens symptoms)
- Children <6 years (both nasal and ophthalmic routes)
- Concurrent use with MAO inhibitors or within 14 days of discontinuation
CAUTIONS
- Hypertension (poorly controlled)
- Cardiovascular disease (coronary artery disease, arrhythmias)
- Hyperthyroidism
- Diabetes mellitus
- Recent ocular surgery (may delay healing)
- Prostatic hypertrophy
- Elderly patients (increased risk of systemic absorption)
- Prolonged or excessive use: risk of rebound congestion or conjunctival hyperaemia
PREGNANCY
| Parameter | Guidance |
| Risk Category | Limited human data; systemic vasoconstriction may affect uteroplacental blood flow |
| Preferred Alternatives | Saline nasal drops (nasal); preservative-free artificial tears (ocular) |
| When to Use | Only if benefit clearly justifies risk; short-term use under supervision |
| Monitoring | Maternal blood pressure; fetal growth monitoring if prolonged use |
LACTATION
| Parameter | Guidance |
| Compatibility | Likely compatible due to minimal systemic absorption |
| Preferred Alternatives | Saline nasal drops; lubricating eye drops |
| Expected Milk Levels | Negligible with topical use |
| Infant Monitoring | Observe for sedation, poor feeding, irritability (rare) |
ELDERLY
- Recommended starting formulation: Lowest effective concentration (e.g., 0.01% ophthalmic)
- Need for slower titration: Yes; increased risk of systemic absorption
- Extra risks: Precipitation of angle-closure glaucoma, cardiovascular effects (hypertension, arrhythmias), CNS effects (dizziness, confusion)
- Duration: Strictly limit to <3 days
- Counsel: Avoid concurrent sympathomimetics or antihypertensives without medical supervision
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Risk |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) |
Contraindicated — severe hypertensive crisis risk
|
| Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline) | Enhanced pressor response; reduced naphazoline metabolism |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Risk |
| Beta-blockers | Additive bradycardia; potential hypotensive effects |
| CNS depressants (benzodiazepines, opioids) | Additive sedation if significant systemic absorption occurs |
| Antihypertensives | May reduce antihypertensive efficacy |
| Other sympathomimetics | Additive cardiovascular effects |
COMMON ADVERSE EFFECTS
- Transient stinging or burning at application site
- Local irritation or dryness (nasal or ocular)
- Sneezing (nasal use)
- Mydriasis (pupillary dilation) with ocular use
- Rebound redness (ocular) or congestion (nasal) with prolonged use
- Headache
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Notes |
| CNS depression | Especially in children and elderly; drowsiness, lethargy, coma |
| Bradycardia and hypotension | With significant systemic absorption |
| Acute angle-closure glaucoma | In predisposed individuals (shallow anterior chamber) |
| Respiratory depression | Particularly in infants and young children |
| Severe allergic reactions | Rare; discontinue immediately if occurs |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Rule out narrow-angle glaucoma before ophthalmic use; assess cardiovascular status |
| After initiation | Monitor for systemic effects (especially in children and elderly) |
| Long-term | Avoid chronic use; reassess if symptoms persist beyond 3–5 days; watch for rebound phenomena |
BRANDS AVAILABLE IN INDIA
- Naphcon-A® (ophthalmic; contains naphazoline + pheniramine)
- Eye-Mo Redness Relief®
- Napcon®
- Coldact Nasal Drops®
- Xyloflo-N®
- Various generic formulations available
Note: Many ophthalmic preparations are available as FDCs with antihistamines (e.g., pheniramine) or other agents.
PRICE RANGE (INR)
| Formulation | Approximate Cost |
| Eye drops 0.01–0.05% (10 mL) | ₹15–₹40 |
| Nasal drops 0.05% (10 mL) | ₹20–₹45 |
- Not listed under NLEM price control
- Prices reflect private pharmacy retail rates
CLINICAL PEARLS
- Strictly limit use to ≤3–5 days to prevent rebound congestion (rhinitis medicamentosa) or rebound ocular redness
- Avoid in children <6 years — high risk of systemic toxicity including CNS depression, bradycardia, and respiratory compromise
- Prefer lower concentrations (0.01%) in elderly patients or those at risk of glaucoma
- Do not combine with MAO inhibitors — risk of severe hypertensive crisis
- Educate patients: Do not share dropper bottles; replace cap immediately after use
- Consider alternatives: For chronic symptoms, investigate underlying cause rather than continuing decongestants
TAGS
naphazoline; ocular decongestant; nasal decongestant; alpha agonist; conjunctivitis; rhinitis; rebound congestion; paediatric caution; glaucoma caution; OTC India
VERSION
RxIndia v0.2 — 18 Feb 2026
REFERENCES
- CDSCO product inserts
- Indian Pharmacopoeia (IP)
- National Formulary of India (NFI)
- API Textbook of Medicine
- AIIMS Paediatric ENT guidance
- IAP Paediatric Handbook
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.